More than 20% surge for NTU after receiving $5.5 million payment

|

Published 13-JAN-2017 13:52 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in emerging dysprosium producer, Northern Minerals (ASX:NTU) were up 22.7% in yesterday’s afternoon trading after the company announced that it had received part payment of $5.5 million from Huatai Mining in respect to the outstanding $18 million in subscription payments, which relates to an equity investment in NTU’s Browns Range project.

It should be noted historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

The key issue behind the delay in payment which was originally due in 2016 related to recent policy changes by the State Administration of Foreign Exchange of China (SAFE), restricting the ability of Chinese entities to effect foreign currency transactions.

Consequently, it appeared at the time that the management of NTU was justifiably confident of full payment being received by January 31.

No doubt, news that the company has received circa 30% of the payment within a matter of days will assist in boosting investor confidence that this matter will be quickly resolved, a welcome development for management given that the issue has arguably placed a drag on the company’s share price in recent months.

The completion of this transaction will facilitate the company’s commitment to establish a pilot plant at Browns Range, and maintain the company’s position to become the world’s first significant producer of dysprosium outside of China.

Today’s rally has occurred under relatively strong volumes of 1.3 million shares, and the company is now within striking distance of its 12 month high of 17.5 cents.

It is worth bearing in mind based on today’s response that payment of the remaining $12.5 million later in the month could be a share price catalyst.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X